Infertilités endocriniennes féminines en dehors du syndrome des ovaires polykystiques

  • N. Chabbert-Buffet
Chapter

Résumé

Les causes endocriniennes en dehors du syndrome des ovaires polykystiques représentent une relativement faible proportion des causes d’infertilité féminine. Elles rentrent dans le cadre des troubles ovulatoires, qui correspondent à 30% des causes féminines d’infertilité. Cependant, parmi ces dysovulations, la plus grande part est en relation avec un syndrome des ovaires polykystiques dont la fréquence dans la population générale est évaluée de 4 à 26% selon la population étudiée et les critères diagnostiques utilisés (1). Parmi les femmes ayant une infertilité d’origine endocrine, il représente 80% des cas (2).

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) (2004) Human reproduction (Oxford, England) 19:41–47Google Scholar
  2. 2.
    Jonard S, Dewailly D (2001) Actualités sur le syndrome des ovaires polykystiques. Immunoanalyse & Biologie Spécialisée 16:302–305CrossRefGoogle Scholar
  3. 3.
    Edwards RG, Lobo R, Bouchard P (1996) Time to revolutionize ovarian stimulation. Human reproduction (Oxford, England) 11:917–919Google Scholar
  4. 4.
    ANAES (1996) Stérilité du couple. Recommandations et références médicales. wwwanaesfrGoogle Scholar
  5. 5.
    Schwartz JL, Creinin MD, Pymar HC et al. (2002) Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 99:177–182PubMedCrossRefGoogle Scholar
  6. 6.
    Landgren BM, Unden AL, Diczfalusy E (1980) Hormonal profile of the cycle in 68 normally menstruating women. Acta Endocrinol 94:89–98PubMedGoogle Scholar
  7. 7.
    Bukulmez O, Arici A (2004) Luteal phase defect: myth or reality. Obstetrics and Gynecol Clin North Am 31:727–744CrossRefGoogle Scholar
  8. 8.
    Young J, Tardy V, Brac de la Perrière A et al. (2010) French Society of Endocrinology — 2008 Consensus: Detection and Management of Late-Onset 21-Hydroxylase Deficiency in Women with Hyperandrogenism. Ann Endocrinol 71:14–18CrossRefGoogle Scholar
  9. 9.
    Zorn JR (2006) Place actuelle du test de Hühner dans l’exploration de la stérilité conjugale. Gynécologie Obstétrique & Fertilité 34:142–146CrossRefGoogle Scholar
  10. 10.
    Caron P, Chauvin S, Christin-Maitre S et al. (1999) Resistance of hypogonadic patients with mutated GnRH receptor genes to pulsatile GnRH administration. The Journal of clinical endocrinology and metabolism 84:990–996PubMedCrossRefGoogle Scholar
  11. 11.
    Mohamed KA, Davies WA, Lashen H (2006) Antimullerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril 86:1515–1517PubMedCrossRefGoogle Scholar
  12. 12.
    Streuli I, Fraisse T, Pillet C et al. (2008) Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 90:395–400PubMedCrossRefGoogle Scholar
  13. 13.
    La Marca A, Giulini S, Orvieto R et al. (2005) Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Human reproduction (Oxford, England) 20:1569–1572CrossRefGoogle Scholar
  14. 14.
    Fraisse T, Ibecheole V, Streuli I et al. (2008) Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil Steril 89:723–729PubMedCrossRefGoogle Scholar
  15. 15.
    Younis JS, Jadaon J, Izhaki I et al. (2010) A simple multivariate score could predict ovarian reserve, as well as pregnancy rate, in infertile women. Fertil Steril 94:655–661PubMedCrossRefGoogle Scholar
  16. 16.
    Levy T, Orvieto R, Homburg R et al. (1996) Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. Human reproduction (Oxford, England) 11:1177–1179Google Scholar
  17. 17.
    Salihu HM, Lynch ON, Alio AP et al. (2009) Extreme maternal underweight and feto-infant morbidity outcomes: a population-based study. J Maternal-Fetal & Neonatal Med 22:428–434CrossRefGoogle Scholar
  18. 18.
    Pizzi C, Evans SA, De Stavola BL et al. (2008) Lifestyle of UK commercial aircrews relative to air traffic controllers and the general population. Aviation, space, & Environ Med 79:964–974CrossRefGoogle Scholar
  19. 19.
    Dode C, Hardelin JP (2009) Kallmann syndrome. Eur J Hum Genet 17:139–146PubMedCrossRefGoogle Scholar
  20. 20.
    Bringer J, Boulet F, Clouet S et al. (1990) Pulsatile administration of gonadotropin releasing hormone in the female. Diagnostic and therapeutic indications. Presse Med 19:1276–1281PubMedGoogle Scholar
  21. 21.
    Christin-Maitre S, de Crecy M (2007) Pregnancy outcomes following pulsatile GnRH treatment: results of a large multicenter retrospective study. J Gynecol Obstet Biol Reprod (Paris) 36:8–12CrossRefGoogle Scholar
  22. 22.
    Martin K, Hall J, Adams J et al. (1993) Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 77:125–129PubMedCrossRefGoogle Scholar
  23. 23.
    The European Recombinant Human LH Study Group (1998) Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH-and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 83:1507–1514CrossRefGoogle Scholar
  24. 24.
    Tsilchorozidou T, Conway GS (2004) Uterus size and ovarian morphology in women with isolated growth hormone deficiency, hypogonadotrophic hypogonadism and hypopituitarism. Clinical Endocrinology 61:567–572PubMedCrossRefGoogle Scholar
  25. 25.
    de Muinck Keizer-Schrama SM (2007) Introduction and management of puberty in girls. Horm Res 68 Suppl 5:80–83CrossRefGoogle Scholar
  26. 26.
    Campo S, Campo V, Lanzone A (2002) Twin pregnancy using recombinant gonadotropins in a woman with hypogonadotropic hypogonadism. Gynecol Endocrinol 16:27–32PubMedGoogle Scholar
  27. 27.
    Brue T, Delemer B (2007) Diagnosis and management of hyperprolactinemia: expert consensus — French Society of Endocrinology. Ann Endocrinol (Paris) 68:58–64CrossRefGoogle Scholar
  28. 28.
    Bonneville JF, Bonneville F, Cattin F (2005) L’IRM hypophysaire: indications et résultats en gynécologie et en obstétrique. Gynécol Obst & Fertil 33:147–153CrossRefGoogle Scholar
  29. 29.
    Abalovich M, Amino N, Barbour LA et al. (2007) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism 92:S1–S47PubMedCrossRefGoogle Scholar
  30. 30.
    HAS (2007) Hypothyroïdies frustes chez l’adulte: diagnostic et prise en charge. www.has-santefr
  31. 31.
    Gibney J, Smith TP, McKenna TJ (2005) Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 62:633–643CrossRefGoogle Scholar
  32. 32.
    Carranza-Lira S, González-Sánchez JL, Martínez-Chequer JC (1999) Vaginal bromocriptine administration in patients with hyperprolactinemia. Intern J Gynecol & Obstet 65:77–78CrossRefGoogle Scholar
  33. 33.
    Darwish AM, Farah E, Gadallah WA et al. (2007) Superiority of Newly Developed Vaginal Suppositories Over Vaginal Use of Commercial Bromocriptine Tablets: A Randomized Controlled Clinical Trial. Reproductive Sciences 14:280–285PubMedCrossRefGoogle Scholar
  34. 34.
    Mendes MC, Ferriani RA, Sala MM et al. (2001) Effect of transitory hyperprolactinemia on in vitro fertilization of human oocytes. J Reprod Med 46:50Google Scholar
  35. 35.
    Nelson LM (2009) Clinical practice. Primary ovarian insufficiency. N Engl J Med 360:606–614PubMedCrossRefGoogle Scholar
  36. 36.
    Bianco B, Lipay M, Guedes A et al. (2009) SRY gene increases the risk of developing gonadoblastoma and/or nontumoral gonadal lesions in Turner syndrome. Int J Gynecol Pathol 28:197–202PubMedCrossRefGoogle Scholar
  37. 37.
    Agence de Biomedecine/CNGOF (2009) Syndrome de Turner et grossesse.http://wwwcngofassofr/D_PAGES/ACCUFRSTHTM
  38. 38.
    Boissonnas CC, Davy C, Bornes M et al. (2009) Careful cardiovascular screening and follow-up of women with Turner syndrome before and during pregnancy is necessary to prevent maternal mortality. Fertil &d Steril 91:929.e925–929.e927Google Scholar
  39. 39.
    Pembrey ME, Barnicoat AJ, Carmichael B et al. (2001) An assessment of screening strategies for fragile X syndrome in the UK. Health Technol Assess 5:1–95PubMedGoogle Scholar
  40. 40.
    Leite-Silva P, Bedone A, Pinto-Neto AM et al. (2009) Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure. Arch Gynecol Obstet 280:177–181PubMedCrossRefGoogle Scholar
  41. 41.
    Uygur D, Sengul O, Bayar D et al. (2005) Bone loss in young women with premature ovarian failure. Arch Gynecol Obstet 273:17–19PubMedCrossRefGoogle Scholar
  42. 42.
    Falhammar H, Thoren M, Hagenfeldt K (2008) A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation. J Endocrinol Invest 31:176–180PubMedGoogle Scholar
  43. 43.
    Nimkarn S, New MI (2009) Prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Mol Cell Endocrinol 300:192–196PubMedCrossRefGoogle Scholar
  44. 44.
    Bachelot A, Chakhtoura Z, Rouxel A et al. (2007) Hormonal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Endocrinol (Paris) 68:274–280Google Scholar
  45. 45.
    Bachelot A, Plu-Bureau G, Thibaud E et al. (2007) Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 67:268–276PubMedCrossRefGoogle Scholar
  46. 46.
    Cohen MA, Sauer MV, Lindheim SR (1999) 21-hydroxylase deficiency and Turner’s syndrome: a reason for diminished endometrial receptivity. Fertil & Steril 72:937–939CrossRefGoogle Scholar
  47. 47.
    Haddow JE, Palomaki GE, Allan WC et al. (1999) Maternal Thyroid Deficiency during Pregnancy and Subsequent Neuropsychological Development of the Child. N Engl J Med 341:549–555PubMedCrossRefGoogle Scholar
  48. 48.
    Carp HJ, Meroni PL, Shoenfeld Y (2008) Autoantibodies as predictors of pregnancy complications. Rheumatology (Oxford, England) 47 Suppl 3:iii6–iii8CrossRefGoogle Scholar
  49. 49.
    Alexander EK, Marqusee E, Lawrence J et al. (2004) Timing and Magnitude of Increases in Levothyroxine Requirements during Pregnancy in Women with Hypothyroidism. N Engl J Med 351:241–249PubMedCrossRefGoogle Scholar
  50. 50.
    Laurberg P, Wallin G, Tallstedt L et al. (2008) TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69–75PubMedCrossRefGoogle Scholar
  51. 51.
    Dimitriadis E, White CA, Jones RL et al. (2005) Cytokines, chemokines and growth factors in endometrium related to implantation. Human Reprod Updates 11:613–630CrossRefGoogle Scholar
  52. 52.
    Henson MC, Castracane VD (2006) Leptin in Pregnancy: An Update. Biol Reprod 74:218–229PubMedCrossRefGoogle Scholar
  53. 53.
    Giachini FRC, Carriel V, Capelo LP et al. (2008) Maternal diabetes affects specific extracellular matrix components during placentation. J Anat 212:31–41PubMedCrossRefGoogle Scholar
  54. 54.
    Galettis A, Campbell S, Morris JM et al. (2004) Monocyte Adhesion to Decidual Endothelial Cells Is Increased in Pregnancies Complicated by Type 1 Diabetes but not by Gestational Diabetes. Diabetes Care 27:2514–2515PubMedCrossRefGoogle Scholar
  55. 55.
    Lejeune V (2006) Fausses couches spontanées précoces répétées: quelle prise en charge proposer en 2006 ? Gynécol Obst & Fertil 34:927–937CrossRefGoogle Scholar
  56. 56.
    Jensen DM, Korsholm L, Ovesen P et al. (2009) Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 32:1046–1048PubMedCrossRefGoogle Scholar
  57. 57.
    Langer O (2007) Oral anti-hyperglycemic agents for the management of gestational diabetes mellitus. Obstet Gynecol Clin North Am 34:255–274, ixPubMedCrossRefGoogle Scholar
  58. 58.
    Nicholson W, Bolen S, Witkop CT et al. (2009) Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 113:193–205PubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2011

Authors and Affiliations

  • N. Chabbert-Buffet
    • 1
    • 2
  1. 1.MCU-PH EndocrinologieUPMC UniversitéParis 06
  2. 2.Service de gynécologie obstétrique médecine de la reproductionHôpital TenonParis

Personalised recommendations